Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

11.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.1K
Cancer02:18

Cancer

53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deciphering small sequence differences in T cell receptor-antigen pairing.

Nature communications·2026
Same author

Gene-Specific Analysis of Clonal Hematopoiesis Identifies ASXL1 as a Risk Factor for Lung Cancer.

bioRxiv : the preprint server for biology·2026
Same author

PHKG2 confers resistance of ESCC to cisplatin and enhances CXCL8-dependent immunosuppression to exacerbate tumorigenesis.

Cell death & disease·2026
Same author

Systematic identification of cell-cell interactions associated with the severity of patients with Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026
Same author

CoCo-ST detects global and local biological structures in spatial transcriptomics datasets.

Nature cell biology·2025
Same author

Unravelling the distinct effects of VHL mutations and chromosome 3p loss in clear cell renal cell carcinoma: Implications for prognosis and treatment.

Clinical and translational medicine·2025

Related Experiment Video

Updated: Jan 8, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K

Gene signatures characterizing driver mutations in lung squamous carcinoma are predictive of the progression of

Yupei Lin1,2,3, Venugopalareddy Mekala1,2,3, Jianrong Li1,2,3

  • 1Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

International Journal of Cancer
|December 16, 2025
PubMed
Summary

Tumor gene expression signatures can predict lung squamous cell carcinoma (LUSC) progression from precancerous lesions. These signatures offer insights into early tumorigenesis and immune interactions, aiding early detection and intervention for LUSC.

Keywords:
LUSCcarcinoma in situgene signaturelung cancertumor biomarker

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

733

Related Experiment Videos

Last Updated: Jan 8, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

733

Area of Science:

  • Oncology
  • Genomics
  • Cancer Biology

Background:

  • Lung squamous cell carcinoma (LUSC) is often diagnosed late, hindering early treatment.
  • LUSC progresses through precancerous lesions, but the prognostic value of genomic alterations in these stages is unclear.

Purpose of the Study:

  • To derive transcriptional signatures from LUSC tumors linked to driver genomic aberrations.
  • To assess if these signatures can characterize precancerous lesion stages and predict progression risk.
  • To explore the relationship between these signatures and the tumor immune microenvironment.

Main Methods:

  • Leveraged The Cancer Genome Atlas (TCGA) gene expression data from LUSC tumors.
  • Derived transcriptional signatures for 34 key driver genomic aberrations.
  • Applied signatures to precancerous datasets to evaluate stage characterization and progression prediction.
  • Analyzed correlations with immune cell infiltration and immune checkpoint gene expression.

Main Results:

  • Signatures progressively increased across lesion stages, indicating roles in early tumorigenesis.
  • Several signatures accurately predicted progression of carcinoma in situ (CIS) to invasive cancer.
  • Signature scores showed stronger prognostic association than genomic aberrations alone.
  • Signatures correlated significantly with immune features like CD274 (PD-L1) expression, with stage-dependent variations.

Conclusions:

  • Tumor-derived driver gene expression signatures offer valuable insights into precancerous lesion biology and progression risk.
  • These signatures have potential utility for early detection and intervention strategies in LUSC.
  • Understanding signature-immune interactions provides a dynamic view of cancer evolution.